The combination of ethinylestradiol/cyproterone acetate is temporarily withdrawn from the market in France. Is the measure justified?

Click to increase image sizeClick to decrease image size

Declaration of interest: N. Chabbert-Buffet served on medical advisory boards of Teva Theramex and participated as a speaker in events sponsored by that firm; the honorarium was paid to the account of the Department of Gynaecology. J. J. Amy read a paper at a meeting organised by MSD; the fee has been donated to a NGO. The authors alone are responsible for the content and the writing of the paper.